Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.61 |
| ▸ | LOX | P28300 | 3/20 | 0.61 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | CCR9 | P51686 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384241 | 0.85 | LOXL2 (0.57) | LOXL2LOXSLC13A5FFAR1GSK3A | |
| SCHEMBL13028811 | 0.81 | LOXL2 (0.65) | LOXL2LOXSLC13A5FFAR1GSK3A | |
| SCHEMBL12093687 | 0.81 | LOXL2 (0.65) | LOXL2LOXSLC13A5FFAR1GSK3A | |
| SCHEMBL14486857 | 0.80 | LOXL2 (0.62) | LOXL2LOXSLC13A5FFAR1GSK3A | |
| SCHEMBL22336235 | 0.80 | LOXL2 (0.68) | LOXL2LOXSLC13A5FFAR1GSK3A | |
| SCHEMBL12093676 | 0.80 | LOXL2 (0.62) | LOXL2LOXSLC13A5FFAR1GSK3A | |
| SCHEMBL31583016 | 0.80 | LOXL2 (0.62) | LOXL2LOXSLC13A5FFAR1GSK3A | |
| SCHEMBL6218599 | 0.80 | LOXL2 (0.73) | LOXL2LOXFFAR1 | |
| SCHEMBL2497237 | 0.80 | LOXL2 (0.62) | LOXL2LOXSLC13A5FFAR1GSK3A | |
| SCHEMBL13965739 | 0.79 | LOX (0.53) | LOXL2LOXSLC13A5GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647683-B2 | Hsp70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | LOXL2 3985/4885LOX 2624/4885SLC13A5 4831/4885 |
| US-10647683-B2 | Hsp70 modulators and methods for making and using the same | HSPA2, HSP90AA1, HSP90AB1 | LOXL2 3985/4885LOX 2624/4885SLC13A5 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.